Alveofact Intratracheal Suspension

Resp distress syndrome (RDS) in premature infants.

Prevention in premature infant <1250 g birthwt or w/ evidence of surfactant deficiency Preferably w/in 15 mins of birth. Rescue Preferably by 8 hr of age. 4 mL/kg birth wt(100 mg of phospholipids/kg birth wt) intratracheally up to 4 doses in 1st 48 hr. Doses should not be given more frequently than 6 hrly. To be administered as soon as possible.

None known.

Infants <600 g birth wt. For intratracheal use only.

Not Classi

Transient bradycardia. O2 desaturation, endotracheal tube reflux & blockage, pallor, vasoconstriction, hypotension, HTN, hypocarbia, hypercarbia & apnea.

Natural bovine pulmonary surfactant; replaces deficient endogenous lung surfactant in neonates with respiratory distress syndrome. Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between alveolar surfaces and air.

Alveofact 45 mg/ml Intratracheal Suspension manufactured by ZAS Corporation. Its generic name is Phospholipids.